These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 37935033)
41. Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial. Mashayekhi M; Beckman JA; Nian H; Garner EM; Mayfield D; Devin JK; Koethe JR; Brown JD; Cahill KN; Yu C; Silver H; Niswender K; Luther JM; Brown NJ Diabetes Obes Metab; 2023 Feb; 25(2):570-580. PubMed ID: 36306151 [TBL] [Abstract][Full Text] [Related]
42. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Nauck MA; Quast DR; Wefers J; Meier JJ Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776 [TBL] [Abstract][Full Text] [Related]
43. The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice. Baggio LL; Ussher JR; McLean BA; Cao X; Kabir MG; Mulvihill EE; Mighiu AS; Zhang H; Ludwig A; Seeley RJ; Heximer SP; Drucker DJ Mol Metab; 2017 Nov; 6(11):1339-1349. PubMed ID: 29107282 [TBL] [Abstract][Full Text] [Related]
44. Reductions of food intake and body weight in diet-induced obese rats following chronic treatment with a monomeric peptide multiagonist. Elfers CT; Chichura KS; Ashlaw EF; Chepurny OG; Holz GG; Doyle RP; Roth CL Clin Nutr; 2024 Jul; 43(7):1782-1790. PubMed ID: 38861891 [TBL] [Abstract][Full Text] [Related]
45. Liraglutide, leptin and their combined effects on feeding: additive intake reduction through common intracellular signalling mechanisms. Kanoski SE; Ong ZY; Fortin SM; Schlessinger ES; Grill HJ Diabetes Obes Metab; 2015 Mar; 17(3):285-93. PubMed ID: 25475828 [TBL] [Abstract][Full Text] [Related]
46. A GLP-1/glucagon (GCG)/CCK Zhao S; Yan Z; Du Y; Li Z; Tang C; Jing L; Sun L; Yang Q; Tang X; Yuan Y; Han J; Jiang N Br J Pharmacol; 2022 Sep; 179(17):4360-4377. PubMed ID: 35484823 [TBL] [Abstract][Full Text] [Related]
47. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411 [TBL] [Abstract][Full Text] [Related]
48. Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals. Wu Y; Ji T; Lv J; Wang Z Life Sci; 2020 Sep; 257():118025. PubMed ID: 32598933 [TBL] [Abstract][Full Text] [Related]
49. Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus. Knudsen LB; Secher A; Hecksher-Sørensen J; Pyke C J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):56-63. PubMed ID: 27186357 [TBL] [Abstract][Full Text] [Related]
50. Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction. McLean BA; Wong CK; Kabir MG; Drucker DJ Mol Metab; 2022 Dec; 66():101641. PubMed ID: 36396031 [TBL] [Abstract][Full Text] [Related]
54. Weight-loss maintenance is accompanied by interconnected alterations in circulating FGF21-adiponectin-leptin and bioactive sphingolipids. Fiorenza M; Checa A; Sandsdal RM; Jensen SBK; Juhl CR; Noer MH; Bogh NP; Lundgren JR; Janus C; Stallknecht BM; Holst JJ; Madsbad S; Wheelock CE; Torekov SS Cell Rep Med; 2024 Jul; 5(7):101629. PubMed ID: 38959886 [TBL] [Abstract][Full Text] [Related]
55. Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. Iepsen EW; Zhang J; Thomsen HS; Hansen EL; Hollensted M; Madsbad S; Hansen T; Holst JJ; Holm JC; Torekov SS Cell Metab; 2018 Jul; 28(1):23-32.e3. PubMed ID: 29861388 [TBL] [Abstract][Full Text] [Related]
56. Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog. Gydesen S; Andreassen KV; Hjuler ST; Hellgren LI; Karsdal MA; Henriksen K Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E598-E607. PubMed ID: 28292761 [TBL] [Abstract][Full Text] [Related]
57. Peripheral, but not central, GLP-1 receptor signaling is required for improvement in glucose tolerance after Roux-en-Y gastric bypass in mice. Carmody JS; Muñoz R; Yin H; Kaplan LM Am J Physiol Endocrinol Metab; 2016 May; 310(10):E855-61. PubMed ID: 27026085 [TBL] [Abstract][Full Text] [Related]
58. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys. Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313 [TBL] [Abstract][Full Text] [Related]
59. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797 [TBL] [Abstract][Full Text] [Related]
60. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome. Tzotzas T; Karras SN; Katsiki N Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]